

MelNet update

22 August 2022

Update on review of Quality Statements to Guide Melanoma Diagnosis and Treatment in NZ

The National Melanoma Working Group continue to review and update the [Quality Statements](#) to ensure the document reflects latest research and best practice. The updated Quality Statements are expected to be released on the MelNet website next month - keep an eye on your inbox for more information.

We are hoping to run a series of webinars this year to increase awareness and understanding of the Quality Statements and highlight significant changes that have been made through the review process. Watch this space!

NZ Skin Cancer Primary Prevention and Early Detection Strategy | Review in progress

The [New Zealand Skin Cancer Primary Prevention and Early Detection Strategy](#) 2017 to 2022 is due to expire at the end of this year.

Since 2001, this Strategy has provided direction and priorities for skin cancer prevention and early detection activities in New Zealand. The content of the document has informed the New Zealand Cancer Action Plan 2019 – 2029, Pūrongo Ārai Mate Pukupuku Cancer Prevention Report and the Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand.

The 2017 - 2022 Strategy was prepared and funded by Te Hiringa Hauora/Health Promotion Agency (HPA) and MelNet on behalf of the Skin Cancer Primary Prevention and Early Detection Steering Committee. With HPA's change in strategic direction resulting in a much-reduced skin cancer prevention programme, MelNet on behalf of the Steering Committee invited Te Aho o Te Kahu/Cancer Control Agency to demonstrate their commitment to the prevention of skin cancer by leading and guiding this important work. The Agency have declined this opportunity as it would be a departure from their whole-system, cross-cancer approach.

It is MelNet's position that the Strategy plays an integral role in defining skin cancer primary prevention and early detection in New Zealand. This view is supported by attendees of the 2022 New Zealand Melanoma Summit who identified the review of the Strategy as a key priority for the sector. The MelNet Executive Committee have therefore agreed to assume responsibility for the review process.

We believe the ideal outcome in these circumstances is for the document to be endorsed by Te Aho, so we have invited representation (among others) to sit on the Steering Committee, which is currently being reconvened.

The review process is scheduled to occur over the remainder of the year. As always, we will keep you informed of our progress and we invite any preliminary feedback to the [MelNet Chief Executive](#).

AOMA Summit videos now available | News from MASC Trials

The third Australasian Ocular Melanoma Summit, hosted by MASC Trials, took place online on 30 July 2022. Sessions are now available to watch on the MASC Trials [YouTube Channel](#).



MASC Trials would like to invite clinicians and nurses working in the ocular melanoma field to join the AOMA Advisory group. For more information please email aoma@masc.org.au.

New Melanoma Brain Metastasis Clinical Trial | BETTER trial

More news from MASC Trials: A recently launched trial, funded by a community fundraising campaign, will investigate a new combination treatment for melanoma that has spread to the brain. The BETTER trial will evaluate the safety, tolerability and efficacy of combining the immunotherapy drugs nivolumab and ipilimumab with bevacizumab and targeted radiotherapy in patients with melanoma brain metastases who have symptoms from their disease and are not suitable for surgical treatment.

[Find out more](#)

Tips and tricks

Identify and manage collision lesions

Learn how to identify and manage collision lesions from Professor Giuseppe Argenziano. He provides insights into the dermoscopic features and clinical presentations of collision tumours, including rare cases and real patient examples.

Watch the videos on HealthCert's Blog:

[How to identify collision tumours](#)

[Managing rare collision tumours](#)

Upcoming opportunities and events



The NZSO Conference 2022 on 22 – 25 September features an extensive programme, including a pre-conference day of Special Interest Group meetings, two conference days of scientific sessions and networking opportunities, and a final day designed for the pathologists in attendance.

[More information](#)

[Programme](#)

[Register now](#)



Other upcoming opportunities and events

September
Certificate of Dermoscopy - Online 2 September - 14 October 2022 Online Find out more
European Society for Medical Oncology Congress (ESMO) 9 – 13 September 2022 Paris, France and online Find out more
Dermatopathology for Skin Cancer Clinicians 9 September - 21 October 2022 Online Find out more
Professional Certificate of Skin Cancer Medicine Professional Certificate of Skin Cancer Surgery

October
Professional Certificate of Skin Cancer Medicine Professional Certificate of Skin Cancer Surgery Advanced Certificate of Skin Cancer Surgery 8 October 2022 Melbourne, Australia Find out more
Advanced Certificate of Skin Cancer Medicine Professional Diploma of Skin Cancer Surgery 9 October 2022 Melbourne, Australia Find out more
19th International Congress of the Society for Melanoma Research 17 – 20 October 2022

<p>Advanced Certificate of Skin Cancer Surgery 10 September 2022 Sydney, Australia Find out more</p> <p>Advanced Certificate of Skin Cancer Medicine Professional Diploma of Skin Cancer Surgery 11 September 2022 Sydney, Australia Find out more</p> <p>ASCO Quality Care Symposium 2022 30 September – 1 October 2022 Chicago, USA and online Find out more</p> <p>For more events see the MelNet events calendar</p>	<p>Edinburgh, Scotland Further information</p> <p>Certificate of Dermoscopy - Online 21 October - 2 December 2022 Online Find out more</p> <p>Certificate of Skin Cancer Medicine 22 - 23 October 2022 Melbourne Find out more</p> <p>18th World Congress on Cancers of the Skin 26 – 29 October 2022 Buenos Aires, Argentina and online Find out more</p> <p>Advanced Skin Surgery Workshop 28 - 31 October 2022 Sydney Find out more</p>
--	---

Recent MelNet website postings

Below is a selection of recent **news postings** on the MelNet website. Please visit the [website](#) to view all the latest news items.

[Electronic tumor-infiltrating lymphocytes robust prognostic markers in patients with primary melanoma](#)

[Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors](#)

[Analysis reveals dysfunction of signaling pathways in uveal melanoma, provides theoretical basis for potential clinical application](#)

[Multi-kinase inhibitor afatinib serves as novel candidate for treatment of human uveal melanoma](#)

[Recurrence after surgical resection of first in-transit metastasis is common; patterns differ according to anatomical site](#)

[Possible applications of epidermal growth factor receptor \(EGFR\) inhibitors to overcome drug resistance in melanoma cells](#)

[BRAF plus MEK inhibition shows meaningful activity and outcome in patients with advanced melanoma resistant to anti-PD-1-based immunotherapy](#)

[‘Rainbow pattern’: a dermoscopic sign of invasive melanoma](#)

[Patients with early-stage melanoma welcome ctDNA monitoring](#)

[Favourable immune checkpoint inhibitor outcome of patients with melanoma harbouring FAT1 mutations](#)



Support our work. Donate to MelNet



Join us on facebook